These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 24785399)
1. A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening--a qualitative analysis. Rychetnik L; Doust J; Thomas R; Gardiner R; Mackenzie G; Glasziou P BMJ Open; 2014 Apr; 4(4):e004682. PubMed ID: 24785399 [TBL] [Abstract][Full Text] [Related]
2. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening. Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779 [TBL] [Abstract][Full Text] [Related]
3. Should women aged 70-74 be invited to participate in screening mammography? A report on two Australian community juries. Degeling C; Barratt A; Aranda S; Bell R; Doust J; Houssami N; Hersch J; Sakowsky R; Entwistle V; Carter SM BMJ Open; 2018 Jun; 8(6):e021174. PubMed ID: 29903796 [TBL] [Abstract][Full Text] [Related]
4. "What should happen before asymptomatic men decide whether or not to have a PSA test?" A report on three community juries. Degeling C; Rychetnik L; Pickles K; Thomas R; Doust JA; Gardiner RA; Glasziou P; Newson AJ; Carter SM Med J Aust; 2015 Oct; 203(8):335. PubMed ID: 26465698 [TBL] [Abstract][Full Text] [Related]
5. PSA testing for men at average risk of prostate cancer. Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854 [TBL] [Abstract][Full Text] [Related]
6. Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer. Mosconi P; Colombo C; Satolli R; Carzaniga S; ; PLoS One; 2016; 11(1):e0143176. PubMed ID: 26751212 [TBL] [Abstract][Full Text] [Related]
7. All care, but whose responsibility? Community juries reason about expert and patient responsibilities in prostate-specific antigen screening for prostate cancer. Degeling C; Carter SM; Rychetnik L Health (London); 2016 Sep; 20(5):465-84. PubMed ID: 27491944 [TBL] [Abstract][Full Text] [Related]
8. Screening for prostate cancer. Ilic D; Neuberger MM; Djulbegovic M; Dahm P Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794 [TBL] [Abstract][Full Text] [Related]
9. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017 [TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Gulati R; Gore JL; Etzioni R Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039 [TBL] [Abstract][Full Text] [Related]
11. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study. Clements A; Watson E; Rai T; Bukach C; Shine B; Austoker J BMC Fam Pract; 2007 Jun; 8():35. PubMed ID: 17593306 [TBL] [Abstract][Full Text] [Related]
12. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians]. Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F; Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008 [TBL] [Abstract][Full Text] [Related]
13. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening. Li J; Zhao G; Hall IJ Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening practices in a large, integrated health system: 2007-2014. Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034 [TBL] [Abstract][Full Text] [Related]
15. National evidence on the use of shared decision making in prostate-specific antigen screening. Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816 [TBL] [Abstract][Full Text] [Related]
16. Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study. Partin MR; Lillie SE; White KM; Wilt TJ; Chrouser KL; Taylor BC; Burgess DJ Health Expect; 2017 Aug; 20(4):779-787. PubMed ID: 27807905 [TBL] [Abstract][Full Text] [Related]
17. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399 [TBL] [Abstract][Full Text] [Related]
18. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment. Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490 [TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening. Sikaris K Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]